Gegenanzeigen · Retacrit
Retacrit 1 000 IU/0.3 mL solution for injection in pre-filled syringe Retacrit 2 000 IU/0.6 mL solution for injection in pre-filled syringe Retacrit 3 000 IU/0.9 mL solution for injection in pre-filled syringe Retacrit 4 000 IU/0.4 mL solution for injection in pre-filled syringe Retacrit 5 000 IU/0.5 mL solution for injection in pre-filled syringe Retacrit 6 000 IU/0.6 mL solution for injection in pre-filled syringe Retacrit 8 000 IU/0.8 mL solution for injection in pre-filled syringe Retacrit 10 000 IU/1 mL solution for injection in pre-filled syringe Retacrit 20 000 IU/0.5 mL solution for injection in pre-filled syringe Retacrit 30 000 IU/0.75 mL solution for injection in pre-filled syringe Retacrit 40 000 IU/1 mL solution for injection in pre-filled syringe · Abschnitt 4.3 · PDF-Seite 10
HOS-119576 · Präparat HOS-094973
The use of Retacrit in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-20T16:27:00Z · SHA-256 85c4780ee223a9afb0db74c1b931ee10d15ab69c223b49e059f55799c892bb2d · Passage e1f4b7e4eebda7994e8c5194a043f6b4a081fd4a693aa565479422d0be0680d9 · Zeichen 436–779 im Abschnitt